Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056611 · ClinicalTrials.gov registry record · Phase 2
Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
A Phase 2 study, sponsored by Janssen Sciences Ireland UC.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04056611 is a Phase 2 study that was terminated before completion, run by Janssen Sciences Ireland UC. The registered enrollment target is 3 participants.
The verdict
NCT04056611, a Phase 2 study, was terminated before completion, sponsored by Janssen Sciences Ireland UC.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.
Interventions
- DRUG Placebo
- DRUG JNJ-53718678 250 mg
- DRUG JNJ-53718678 125 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-12-26 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04056611
The ClinicalTrials.gov registry entry for NCT04056611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Sciences Ireland UC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04056611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04056611 about?
NCT04056611 is a clinical study titled "Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)". The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.
What is the current status of trial NCT04056611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-12-26. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT04056611?
The interventions under investigation include: Placebo (DRUG), JNJ-53718678 250 mg (DRUG), JNJ-53718678 125 mg (DRUG).
Who is sponsoring clinical trial NCT04056611?
This trial is sponsored by Janssen Sciences Ireland UC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.